NCT07542379 2026-04-21
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
8 trialsNCT07468708 2026-04-17
The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07505771 2026-04-06
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
Immunome, Inc.
Phase EARLY_PHASE1 Recruiting
NCT06736275 2026-04-03
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
Jiangsu Nutai Biologics Co., Ltd
Phase EARLY_PHASE1 Completed
NCT07033689 2026-04-03
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
SONIRE Therapeutics Inc.
Phase EARLY_PHASE1 Recruiting
NCT07505069 2026-04-01
Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
Nanolattix Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07376642 2026-03-30
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1 Recruiting
NCT07493135 2026-03-30
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1 Recruiting